ST HULUWA has obtained the drug registration certificate for Cefdinir Capsules
ST HULUWA recently obtained the drug registration certificate for Cefdinir capsules approved by the National Medical Products Administration. Cefdinir is a third-generation broad-spectrum cephalosporin, suitable for infections caused by various bacteria, including pharyngitis, pneumonia, and otitis media. The approval of this drug meets the technical requirements for the consistency evaluation of quality and efficacy of generic drugs
According to the announcement from Zhitong Finance APP, ST HULUWA (605199.SH) has recently received the "Drug Registration Certificate" for Cefdinir capsules approved and issued by the National Medical Products Administration (referred to as "NMPA").
Cefdinir is a third-generation broad-spectrum cephalosporin antibiotic, which is suitable for treating infections caused by strains sensitive to Cefdinir, including Staphylococcus, Streptococcus, Streptococcus pneumoniae, Enterococcus, Propionibacterium, Neisseria gonorrhoeae, Moraxella catarrhalis, Escherichia coli, Klebsiella, Proteus mirabilis, Providencia, Haemophilus influenzae, and others. The infections include: pharyngitis, tonsillitis, acute bronchitis, pneumonia; otitis media, sinusitis; pyelonephritis, cystitis, gonococcal urethritis; adnexitis, intrauterine infections, Bartholin's gland inflammation; mastitis, perianal abscess, secondary infections of traumatic or surgical wounds; folliculitis, boils, carbuncles, abscesses, infectious pustular disease, erysipelas, cellulitis, lymphangitis, paronychia, subcutaneous abscesses, cyst infections, chronic suppurative dermatitis; blepharitis, stye, meibomian gland inflammation. This drug has been reviewed and approved according to the technical requirements consistent with the quality and efficacy of the reference preparation, and upon approval, it is considered to have passed the consistency evaluation of generic drug quality and efficacy
